Use of anti-inflammatory agents in clinical islet cell transplants: A qualitative systematic analysis.

IF 1.9 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Islets Pub Date : 2019-01-01 DOI:10.1080/19382014.2019.1601543

Kristen R Szempruch, Oyshik Banerjee, Rebecca C McCall, Chirag S Desai

{"title":"Use of anti-inflammatory agents in clinical islet cell transplants: A qualitative systematic analysis.","authors":"Kristen R Szempruch, Oyshik Banerjee, Rebecca C McCall, Chirag S Desai","doi":"10.1080/19382014.2019.1601543","DOIUrl":null,"url":null,"abstract":"<p><p>Immunologic and non-immunologic loss of islet cells upon their transplantation into the liver leads to suboptimal outcomes. Anti-inflammatory agents are used during autologous and allogeneic transplantation. The aim of this qualitative systematic literature review is to evaluate their clinical use and safety. Electronic databases Embase, PubMed, Cumulative Index for Nursing and Allied Health Literature, ClinicalTrials.gov, and EU Clinical Trials Register were searched. Of the 216 unique citations, 10 with tumor necrosis factor (TNF) blockers [etanercept (ETA) or infliximab] and 3 with both TNF blockers and an interluekin-1 receptor antagonist [anakinra (ANA)]) were included. Of these, 12 were in allogeneic and one in autologous transplant. Insulin independence with decreased islet cells and number of transfusions were reported with their use. One infection was reported in a group receiving ETA. Analysis suggested that the use of ETA ± ANA have the potential to improve outcomes in islet cell transplant.</p>","PeriodicalId":14671,"journal":{"name":"Islets","volume":"11 3","pages":"65-75"},"PeriodicalIF":1.9000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/19382014.2019.1601543","citationCount":"22","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Islets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/19382014.2019.1601543","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 22

Abstract

Immunologic and non-immunologic loss of islet cells upon their transplantation into the liver leads to suboptimal outcomes. Anti-inflammatory agents are used during autologous and allogeneic transplantation. The aim of this qualitative systematic literature review is to evaluate their clinical use and safety. Electronic databases Embase, PubMed, Cumulative Index for Nursing and Allied Health Literature, ClinicalTrials.gov, and EU Clinical Trials Register were searched. Of the 216 unique citations, 10 with tumor necrosis factor (TNF) blockers [etanercept (ETA) or infliximab] and 3 with both TNF blockers and an interluekin-1 receptor antagonist [anakinra (ANA)]) were included. Of these, 12 were in allogeneic and one in autologous transplant. Insulin independence with decreased islet cells and number of transfusions were reported with their use. One infection was reported in a group receiving ETA. Analysis suggested that the use of ETA ± ANA have the potential to improve outcomes in islet cell transplant.

Abstract Image

查看原文本刊更多论文

抗炎药在临床胰岛细胞移植中的应用:定性系统分析。

胰岛细胞移植到肝脏后的免疫和非免疫损失导致不理想的结果。抗炎药用于自体和异体移植。本定性系统文献综述的目的是评价它们的临床应用和安全性。检索电子数据库Embase、PubMed、护理和相关健康文献累积索引、ClinicalTrials.gov和EU临床试验注册。在216篇独特的引文中，10篇涉及肿瘤坏死因子(TNF)阻滞剂[依那西普(ETA)或英夫利昔单抗]，3篇涉及TNF阻滞剂和白细胞介素-1受体拮抗剂[阿那金那(ANA)])。其中12例为同种异体移植，1例为自体移植。胰岛素独立性与胰岛细胞减少和输血次数的报道与他们的使用。在接受ETA治疗的一组中报告了一例感染。分析表明，使用ETA±ANA有可能改善胰岛细胞移植的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Islets ENDOCRINOLOGY & METABOLISM-

CiteScore

3.30

自引率

4.50%

发文量

审稿时长

>12 weeks

期刊介绍： Islets is the first international, peer-reviewed research journal dedicated to islet biology. Islets publishes high-quality clinical and experimental research into the physiology and pathology of the islets of Langerhans. In addition to original research manuscripts, Islets is the leading source for cutting-edge Perspectives, Reviews and Commentaries. Our goal is to foster communication and a rapid exchange of information through timely publication of important results using print as well as electronic formats.